Drug Profile

HP 537

Alternative Names: HP-537

Latest Information Update: 04 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hinova pharmaceuticals
Class Antineoplastics
Mechanism of Action P300-CBP transcription factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Haematological malignancies
No development reported Breast cancer; Cancer; Prostate cancer

Most Recent Events

04 Sep 2026 HP 537 is still in preclinical development for Haematological malignancies in China (Hinova Pharmaceuticals pipeline, September 2026)
28 Jun 2026 No recent reports of development identified for preclinical development in Breast-cancer in China
28 Feb 2025 No recent reports of development identified for preclinical development in Cancer in China

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com